Rare genitourinary neoplasms encompass diseases of the kidney, bladder, prostate, and penile tract that are of uncommon histology. These entities often pose a major diagnostic and treatment dilemma to the treating physician.
CT imaging is widely available and contains quantitative information, particularly with respect to measuring changes in tumor size. However, there are many differences in how tumor size and response are assessed in clinical trials compared with clinical practice.
In women with platinum-sensitive relapsed ovarian cancer, maintenance therapy with olaparib does not provide a significant overall survival benefit, but long-term therapy is possible, according to an updated analysis of a randomized, double-blind phase II study.
Consideration of clinical trial data and anecdotal patient information can help oncologists weigh available treatment options to either help delay disease progression or avoid hormone therapy for patients with oligometastatic prostate cancer.
In women with platinum-resistant or platinum-refractory recurrent ovarian cancer, health-related quality of life appears to predict early cessation of chemotherapy and shorter overall survival, and is more sensitive than ECOG performance status, based on an international prospective cohort study.